A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

Current Medical Research and Opinion

Volumn 19, Issue 8, 2003, Pages 725-736

  Zacher, J ^a   Feldman, D ^b   Gerli, R ^c   Scott, D ^d   Hou, S M ^e   Uebelhart, D ^f   Rodger, I W ^g   Ozturk, Zafer E ^g  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Ctr for the Stud of Rheum Dis   (Italy)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cox 2 inhibitor; Diclofenac; Etoricoxib; Non steroidal anti inflammatory drugs; NSAIDs; Osteoarthritis

Indexed keywords

DICLOFENAC; ETORICOXIB; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PAIN ASSESSMENT; PATIENT; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECORDING; SKIN DISEASE; TIME; TREATMENT OUTCOME; WALKING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PYRIDINES; SULFONES; TREATMENT OUTCOME; UNITED STATES;

EID: 0345276666     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002469     Document Type: Article

References (42)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503-9
3. Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effects of demographic and psychological variables using three pain measures. J Rheumatol 1999;26:1785-92
4. Hochberg, MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40
5. Hochberg, MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6
6. FitzGerald GA, Patrono C. The coxibs; selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42
7. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding and perforation: an overview of epidemiological studies published in the 1990s. Arch Intern Med 2000;160:2093-9
8. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18(Suppl 28):6-10
9. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14
10. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events associated with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92
11. Hunt RH, Bowen B, Mortensen E, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen or placebo in healthy subjects. Am J Med 2000;109:201-6
12. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10
13. Vane JR, Botting RM. The future of NSAID therapy: selective COX-2 inhibitors. Int J Clin Pract 2000;54:7-9
14. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19
15. Shorrock CJ, Rees WDW. Overview of gastroduodenal mucosal protection. Am J Med 1988;(Suppl 2A):25-34
16. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. J Biol Chem 1996;271:33157-60
17. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20
18. Vane JR, Bakhle YS, Botting RM. Cyclo-oxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120
19. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
20. Hawkey CJ, Jackson L, Harper SE, et al. Review article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2 in humans. Aliment Pharmacol Ther 2001;15:1-9
21. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33
22. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
23. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable to that of diclofenac sodium: results of a one-year, randomized clinical trial in patients with osteoarthritis of the knee or hip. Arthritis Rheum 2000;43:978-87
24. Ehrich EW, Bolognese JA, Watson DJ, Kong, S. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care 2001;7:609-16
25. Emery P, Zeidler, H, Kvien KT, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999;354:2106-11
26. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee. JAMA 2002;287:64-71
27. Riendeau D, Percival D, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-66
28. Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin Pharmacother 2003;4:265-84
29. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58
30. Matsumoto AK, Melian A, Mandel DR, et al. A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30
31. Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002;3:10-19
32. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1999;15:1833-40
33. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase-2 inhibitor shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34
34. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7
35. Dougados M, LeClaire P, van der Heijde D, et al. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the osteoarthritis research society international standing committee for clinical trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395-403
36. Skoutakis VA, Carter CA, Mickle TR, et al. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal anti-inflammatory agent. Drug Intell Clin Pharm 1988;22:850-9
37. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988;35:144-85
38. Agrawal NG, Porras AG, Matthews CZ, et al. Dose-proportionality of etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-10
39. Agrawal NG, Porras AG, Matthews CZ, et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;43:268-76
40. Schumacher HR, Boice JA, Daikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-92
41. Fisher C, Bockow B, Curtis SP, et al. Results of a 190-week randomized study demonstrated similar efficacy of etoricoxib compared with diclofenac in patients with osteoarthritis. Ann Rheumatic Dis 2003;62(Suppl 1):272
42. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995;22:820-7